Eugenio Fernández
- Oncology top 2%
- CAR-T cell therapy research 6
- Cancer Immunotherapy and Biomarkers 2
- Cancer Diagnosis and Treatment 2
- Peptidase Inhibition and Analysis 2
- Immunology top 5%
- Immunotherapy and Immune Responses 3
- Genetics top 5%
- Virus-based gene therapy research 4
- Biotechnology top 5%
- Cancer Research and Treatments 3
- Accounting top 10%
-
- Fibroblast Growth Factor Research 2
- Co-authors
- F. Stephen HodiJosep MalvehyAntoni RibasAnthony J. OlszanskiJonathan CebonOlivier MichielinReinhard DummerThomas F. Gajewski
- Cited by
- OncologyImmunologyGenetics
- Partner nations
- SwitzerlandSpainUnited States
In The Last Decade
Eugenio Fernández
22 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 82
- Oncology 1.1k
- Immunology 589
- Genetics 593
- Biotechnology 130
- Accounting 85
Countries citing papers authored by Eugenio Fernández
This map shows the geographic impact of Eugenio Fernández's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugenio Fernández with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugenio Fernández more than expected).
Fields of papers citing papers by Eugenio Fernández
This network shows the impact of papers produced by Eugenio Fernández. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugenio Fernández. The network helps show where Eugenio Fernández may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Eugenio Fernández, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2023 | 7 | |
| 3 | 2022 | 13 | |
| 4 | 2022 | 4 | |
| 5 | 2022 | 1 | |
| 6 | 2021 | 26 | |
| 7 | 2021 | 4 | |
| 8 | 2020 | 0 | |
| 9 | [Rheumatological complications of immune checkpoint inhibitor therapy]. | 2020 | 1 |
| 10 | 2017 | 2 | |
| 11 | Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapybreakdown → | 2017 | 1142 |
| 12 | 2017 | 6 | |
| 13 | 2016 | 1 | |
| 14 | [Maintenance chemotherapy: futility or utility?]. | 2015 | 1 |
| 15 | 2015 | 23 | |
| 16 | TOWARDS AN IT QUALITY MATURITY MODEL | 2012 | 0 |
| 17 | MMCbEEES: Maturity model in the e-Learning teaching environment adapted to the EHEA | 2011 | 1 |
| 18 | 2010 | 2 | |
| 19 | 2003 | 2 | |
| 20 | 2003 | 9 |
About Eugenio Fernández
Eugenio Fernández is a scholar working on Biotechnology, Oncology and Computer Science Applications, having authored 25 papers that have together received 1.5k indexed citations. Recurring topics across this work include CAR-T cell therapy research (6 papers), Virus-based gene therapy research (4 papers), Cancer Research and Treatments (3 papers), Immunotherapy and Immune Responses (3 papers), Fibroblast Growth Factor Research (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Cancer Diagnosis and Treatment (2 papers) and Peptidase Inhibition and Analysis (2 papers). The work is most often cited by research in Oncology (1.1k citations), Immunology (589 citations) and Genetics (593 citations). Eugenio Fernández has collaborated with scholars based in Switzerland, Spain and United States. Frequent co-authors include F. Stephen Hodi, Josep Malvehy, Antoni Ribas, Anthony J. Olszanski, Jonathan Cebon, Olivier Michielin, Reinhard Dummer, Thomas F. Gajewski, Ari M. Vanderwalde and Georgina V. Long. Their work appears in journals such as Cell, Journal of Clinical Oncology and Cancer Treatment Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.